Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 421

1.

Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt/β-catenin and mTORC1 signaling in prostate and breast cancer cells.

Lu W, Lin C, Li Y.

Cell Signal. 2014 Jun;26(6):1303-9. doi: 10.1016/j.cellsig.2014.02.018. Epub 2014 Mar 6.

2.

Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.

Lu W, Lin C, Roberts MJ, Waud WR, Piazza GA, Li Y.

PLoS One. 2011;6(12):e29290. doi: 10.1371/journal.pone.0029290. Epub 2011 Dec 16.

3.
4.

Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells.

Lu W, Lin C, King TD, Chen H, Reynolds RC, Li Y.

Cell Signal. 2012 Dec;24(12):2291-6. doi: 10.1016/j.cellsig.2012.07.009. Epub 2012 Jul 20.

5.

Kallistatin antagonizes Wnt/β-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6.

Zhang J, Yang Z, Li P, Bledsoe G, Chao L, Chao J.

Mol Cell Biochem. 2013 Jul;379(1-2):295-301. doi: 10.1007/s11010-013-1654-2. Epub 2013 May 12.

6.

Tyrosine-based signal mediates LRP6 receptor endocytosis and desensitization of Wnt/β-catenin pathway signaling.

Liu CC, Kanekiyo T, Roth B, Bu G.

J Biol Chem. 2014 Oct 3;289(40):27562-70. doi: 10.1074/jbc.M113.533927. Epub 2014 Aug 20.

7.

Inhibition of Wnt/β-catenin signaling mediates ursolic acid-induced apoptosis in PC-3 prostate cancer cells.

Park JH, Kwon HY, Sohn EJ, Kim KA, Kim B, Jeong SJ, Song JH, Koo JS, Kim SH.

Pharmacol Rep. 2013;65(5):1366-74.

8.

Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.

Zhu Y, Wang M, Zhao X, Zhang L, Wu Y, Wang B, Hu W.

Oncotarget. 2017 Apr 4;8(14):22825-22834. doi: 10.18632/oncotarget.15221.

9.

Cripto-1 enhances the canonical Wnt/β-catenin signaling pathway by binding to LRP5 and LRP6 co-receptors.

Nagaoka T, Karasawa H, Turbyville T, Rangel MC, Castro NP, Gonzales M, Baker A, Seno M, Lockett S, Greer YE, Rubin JS, Salomon DS, Bianco C.

Cell Signal. 2013 Jan;25(1):178-89. doi: 10.1016/j.cellsig.2012.09.024. Epub 2012 Sep 27.

10.

Phosphorylation-independent mTORC1 inhibition by the autophagy inducer Rottlerin.

Torricelli C, Daveri E, Salvadori S, Valacchi G, Ietta F, Muscettola M, Carlucci F, Maioli E.

Cancer Lett. 2015 Apr 28;360(1):17-27. doi: 10.1016/j.canlet.2015.01.040. Epub 2015 Feb 4.

PMID:
25661734
11.

The C-terminal region Mesd peptide mimics full-length Mesd and acts as an inhibitor of Wnt/β-catenin signaling in cancer cells.

Lin C, Lu W, Zhang W, Londoño-Joshi AI, Buchsbaum DJ, Bu G, Li Y.

PLoS One. 2013;8(2):e58102. doi: 10.1371/journal.pone.0058102. Epub 2013 Feb 28.

12.

The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer.

King TD, Suto MJ, Li Y.

J Cell Biochem. 2012 Jan;113(1):13-8. doi: 10.1002/jcb.23350. Review.

PMID:
21898546
13.

Role of the Rap2/TNIK kinase pathway in regulation of LRP6 stability for Wnt signaling.

Park DS, Seo JH, Hong M, Choi SC.

Biochem Biophys Res Commun. 2013 Jun 28;436(2):338-43. doi: 10.1016/j.bbrc.2013.05.104. Epub 2013 Jun 4.

PMID:
23743195
14.

Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer.

Arensman MD, Nguyen P, Kershaw KM, Lay AR, Ostertag-Hill CA, Sherman MH, Downes M, Liddle C, Evans RM, Dawson DW.

Mol Cancer Res. 2015 Nov;13(11):1509-19. doi: 10.1158/1541-7786.MCR-15-0204. Epub 2015 Jul 29.

15.

Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells.

Lu W, Liu CC, Thottassery JV, Bu G, Li Y.

Biochemistry. 2010 Jun 8;49(22):4635-43. doi: 10.1021/bi1001486.

16.

Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.

Lemieux E, Cagnol S, Beaudry K, Carrier J, Rivard N.

Oncogene. 2015 Sep 17;34(38):4914-27. doi: 10.1038/onc.2014.416. Epub 2014 Dec 15.

17.

Ganoderma lucidum (Reishi) suppresses proliferation and migration of breast cancer cells via inhibiting Wnt/β-catenin signaling.

Zhang Y.

Biochem Biophys Res Commun. 2017 Jul 8;488(4):679-684. doi: 10.1016/j.bbrc.2017.04.086. Epub 2017 Apr 17.

PMID:
28427938
18.

Role of Wnt Co-Receptor LRP6 in Triple Negative Breast Cancer Cell Migration and Invasion.

Ma J, Lu W, Chen D, Xu B, Li Y.

J Cell Biochem. 2017 Sep;118(9):2968-2976. doi: 10.1002/jcb.25956. Epub 2017 May 30.

PMID:
28247948
19.

LRP6 mediates Wnt/β-catenin signaling and regulates adipogenic differentiation in human mesenchymal stem cells.

Peröbner I, Karow M, Jochum M, Neth P.

Int J Biochem Cell Biol. 2012 Nov;44(11):1970-82. doi: 10.1016/j.biocel.2012.07.025. Epub 2012 Aug 2.

PMID:
22871567
20.

Receptor heterodimerization as a novel mechanism for the regulation of Wnt/β-catenin signaling.

Lee K, Shin Y, Cheng R, Park K, Hu Y, McBride J, He X, Takahashi Y, Ma JX.

J Cell Sci. 2014 Nov 15;127(Pt 22):4857-69. doi: 10.1242/jcs.149302. Epub 2014 Sep 30.

Supplemental Content

Support Center